An intravenous stimulus package for oncolytic virotherapy

. 2011 Nov;19(11):1930-2.

doi: 10.1038/mt.2011.217.

Affiliations

Richard Vile et al. Mol Ther. 2011 Nov.

. 2011 Nov;19(11):1930-2.

doi: 10.1038/mt.2011.217.

¹ Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. vile.richard@mayo.edu

No abstract available

Cited by

Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.
Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumarana S. Biswas M, et al. J Virol. 2012 Dec;86(23):12708-16. doi: 10.1128/JVI.00886-12. Epub 2012 Sep 12. J Virol. 2012. PMID: 22973037 Free PMC article.
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.
Das K, Belnoue E, Rossi M, Hofer T, Danklmaier S, Nolden T, Schreiber LM, Angerer K, Kimpel J, Hoegler S, Spiesschaert B, Kenner L, von Laer D, Elbers K, Derouazi M, Wollmann G. Das K, et al. Nat Commun. 2021 Aug 31;12(1):5195. doi: 10.1038/s41467-021-25506-6. Nat Commun. 2021. PMID: 34465781 Free PMC article.

1. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR., and, Chow LQM. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99–102. - PubMed
1. Chiocca EA. Oncolytic viruses. Nat Rev Cancer. 2002;2:938–950. - PubMed
1. Kirn D, Martuza RL., and, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 2001;7:781–787. - PubMed
1. Policy failure on a massive scale The Economist 28 July 2011.
1. Cut or loose: history suggests that austerity and growth just do not mix . The Economist 14 July 2011;